| Current Price | $28.80 | Mkt Cap | $135.9M |
|---|---|---|---|
| Open | $26.69 | P/E Ratio | 79.46 |
| Prev. Close | $28.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $26.66 - $28.99 | Volume | 1 |
| 52-Wk Range | $8.57 - $37.71 | Avg. Daily Vol. | 77,744 |
The Company is a provider of management software for networks and applications. Its solutions address application performance management, capacity planning and design, network operations, and network research and development.
| Current Price | $28.80 | Mkt Cap | $135.9M |
|---|---|---|---|
| Open | $26.69 | P/E Ratio | 79.46 |
| Prev. Close | $28.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $26.66 - $28.99 | Volume | 1 |
| 52-Wk Range | $8.57 - $37.71 | Avg. Daily Vol. | 77,744 |
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about OPNT.
Recs
cthuhlu
(< 20)
Submitted: 11/29/2021 11:46:52 AM :
Start Price:
$25.27
NASDAQ:OPNT Score:
+15.65
OPNT is a specialty pharmaceutical company that has developed NARCAN and the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for OPNT003, nasal nalmefene, the company's investigational treatment for opioid overdose. The company could file a new drug application with the FDA as early as Q1 2022.
OPNT became profitable again in 2021 and their earning are forecast to grow more than 10% per year for the next 1 to 3 years.
Recs
rspenny
(< 20)
Submitted: 4/19/2020 12:13:15 PM :
Start Price:
$10.48
NASDAQ:OPNT Score:
+113.14
Pharmaceuticals FDA approvals
Recs
kjmurphy15
(< 20)
Submitted: 12/6/2010 5:01:33 PM :
Start Price:
$24.70
NASDAQ:OPNT Score:
-251.73
No Debt, New Products, Leader, Increased Earnings
Find the members with the highest scoring picks in OPNT.
eas6407 (81.39) Score: +342.31
The Score Leader is the player with the highest score across all their picks in OPNT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| SmallCapRoss | < 20 | 1/17/2012 |
|
5Y | $34.05 | -15.42% | +250.95% | +266.36 | 0 Comment | |
| pademauge | < 20 | 1/26/2021 |
|
3M | $9.39 | +206.71% | +18.45% | +188.26 | 0 Comment | |
| MancoraJack | < 20 | 4/6/2021 |
|
5Y | $10.90 | +164.22% | +12.51% | +151.71 | 0 Comment | |
| rspenny | < 20 | 4/20/2020 |
|
5Y | $10.48 | +174.81% | +61.67% | +113.14 | 1 Comment | |
| Guffrey | < 20 |
|
|
5Y | $6.94 | +315.16% | +243.12% | +72.04 | 0 Comment | |
| jemoore567 | < 20 | 3/25/2008 |
|
3W | $6.95 | +314.11% | +251.05% | +63.06 | 0 Comment | |
| davespics1 | < 20 | 3/28/2008 |
|
3M | $7.20 | +300.03% | +255.99% | +44.04 | 0 Comment | |
| CrazyTrout | < 20 | 11/14/2007 |
|
NS | $7.92 | +263.43% | +220.52% | +42.91 | 0 Comment | |
| eblancafort | 74.16 | 11/2/2007 |
|
NS | $8.03 | +258.68% | +217.73% | +40.95 | 0 Comment | |
| tombreadman | 95.60 | 10/22/2019 |
|
5Y | $15.44 | +86.53% | +51.87% | +34.66 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
